Logo for Nykode Therapeutics

Nykode Therapeutics Investor Relations Material

Latest events

Logo for Nykode Therapeutics

Q1 2024

Nykode Therapeutics
Logo for Nykode Therapeutics

Q1 2024

14 May, 2024
Logo for Nykode Therapeutics

Q4 2023

28 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Nykode Therapeutics

Access all reports
Segment Data
Access more data
External revenue by
Geography
U.S.
Expenses by
Financials
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies in the fields of cancer and infectious diseases. The company develops vaccines for the treatment cancer, melanoma, lung, head and neck, renal, bladder cancer; Nkyode Therapeutics AS was formerly known as Vaccibody AS. The Company's lead product candidates include VB10.NEO (Oncolytic Immunotherapy), which has completed Phase I/IIa clinical trial; it also has development collaboration agreements with Roche, Genentech and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; research agreement with Regeneron.